Condition Directory

Obesity clinical trials

Directory of U.S. ClinicalTrials.gov public records for Obesity. Browse Obesity recruiting trials, filter by phase, sponsor, location, or intervention, and open the official ClinicalTrials.gov study record for each result.

By Clinical Trials Finder Guidance last reviewed June 10, 2026 Data synced October 1, 2026 Report an issue

ClinicalTrials.gov public records Last synced Oct 1, 2026, 8:51 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

2303

Shown on this page

Current sort

How Obesity studies are organized in the registry

Obesity research spreads across several neighboring registry terms — “overweight,” “weight loss,” and “metabolic syndrome” all label closely related studies — so checking more than one term gives a fuller picture. The portfolio includes many behavioral and lifestyle studies alongside drug trials, which makes the study-type filter (interventional vs. observational) more informative than usual.

Terms that often appear in related listings

weight loss overweight metabolic syndrome bariatric

These describe how studies tend to be titled and grouped on ClinicalTrials.gov — they are search vocabulary, not medical guidance.

Showing 13–24 of 2,303 matching trials for Obesity.

Live ClinicalTrials.gov results.

Active filters: "weight loss" Clear condition filters

Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Open in full search

Conditions: Obesity
Interventions: CagriSema (Cagrilintide B and Semaglutide I), Placebo matched to CagriSema (Cagrilintide B and Semaglutide I); Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 609 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 47
States / cities: Costa Mesa, California • San Diego, California • Walnut Creek, California + 42 more

Conditions: Obesity
Interventions: Survodutide, Placebo; Combination Product
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 45 Years to 65 Years · Female only
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Riverview, Florida

Conditions: Obesity & Overweight, Prediabetes
Interventions: Precision Nutrition Intervention, Standard Nutrition Counseling; Behavioral
Lead sponsor: Prairie View A&M University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Prairie View, Texas

Conditions: Overweight, Obesity
Interventions: Cagrilintide, Semaglutide, Placebo cagrilintide, Placebo semaglutide; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 8 Years to 18 Years
Enrollment: 460 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2033
U.S. locations: 34
States / cities: Escondido, California • Hollywood, Florida • Jacksonville, Florida + 29 more

Conditions: Obesity, Type 2 Diabetes
Interventions: Cagrisema, Semaglutide; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 2,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 99
States / cities: Birmingham, Alabama • Pelham, Alabama • Gilbert, Arizona + 81 more

Conditions: Obese Adults
Interventions: SC VK3019, Matching placebo; Drug
Lead sponsor: Viking Therapeutics, Inc.; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: Lake Forest, California

Conditions: Obesity, Overweight
Interventions: LY3841136, Tirzepatide, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 367 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 48
States / cities: Chandler, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 42 more

Conditions: Obesity, Overweight and/or Obesity, Overweight, Treatment Of Obesity
Interventions: Semaglutide, Tirzepatide, Berobenatide; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 660 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 8
States / cities: Birmingham, Alabama • New Port Richey, Florida • Louisville, Kentucky + 5 more

Conditions: Obesity &Amp; Overweight
Interventions: Cardiovascular Exercise, Butyrate; Behavioral · Dietary Supplement
Lead sponsor: Texas Christian University; Other
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Fort Worth, Texas

Conditions: Obesity, Overweight
Interventions: BI 3034701, Placebo matching BI 3034701; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years to 74 Years
Enrollment: 344 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 19
States / cities: Birmingham, Alabama • West Hills, California • Miami, Florida + 16 more

Conditions: Apnea, Sleep Disorders, Overweight and/or Obesity
Interventions: Berobenatide, Placebo; Drug · Other
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 258 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 3
States / cities: Cullman, Alabama • Bradenton, Florida • Maplewood, Minnesota

Conditions: Obesity and Overweight, Diabetes Mellitus, Weight Loss, Behavior Change
Interventions: Family Skills Training Session Quantity: 5, Family Skills Training Session Mode: In-person, Family Skills Training Content: Communication, Family Skills Training Content: Cohesion, Family Skills Training Session Quantity: 10, Family Skills Training Session Mode: Online, Family Skills Training Content: No Communication, Family Skills Training Content: No Cohesion; Behavioral
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 75 Years
Enrollment: 256 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

About this Obesity clinical trials directory page

What this page lists: U.S. ClinicalTrials.gov public records that list Obesity as a study condition, including recruiting, not yet recruiting, and active not recruiting trials across phase 1, phase 2, and phase 3.
How to narrow results: Use the filters above to scope by intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Obesity.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.

Obesity clinical trials

How Obesity studies are organized in the registry

Filter and sort this condition

Live official records

A Research Study to Look at How Well CagriSema Helps People Living With Obesity Lose Weight and Maintain Weight Loss in the Long-term

SYNCHRONIZE®-HERA: A Study to Test Whether Survodutide Helps Women Who Are Living With Overweight or Obesity and Are Going Through or Have Finished Menopause, to Lose Weight

Precision Nutrition for Obesity and Prediabetes Prevention in Under-supported Communities

A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight

A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight

A Phase 1 Study of VK3019 in Overweight and Obese Adults Without Comorbidities

A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 Diabetes

A Study to Learn About Switching to a Monthly Study Medicine Called Berobenatide (PF-08653944) to Help Keep Weight Off in People With Overweight or Obesity

Can Gut Bacteria Predict Who Benefits Most From Exercise? A Gut Supplement to Help Exercise Non-Responders

A Study to Test Whether BI 3034701 Helps People to Lose Weight Who Live With Obesity or Overweight

A Study to Learn About the Monthly Dosing Study Medicine Called Berobenatide in Adults With Breathing Problems During Sleep and Overweight or Obesity Who Use a Breathing Machine (PAP) (VESPER-OSA 1)

FAMily-centered WEight Loss for Black Adults (FAM WEL B-ing)

About this Obesity clinical trials directory page